NON-SELECTIVE BETA-BLOCKERS IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES: WHERE ARE WE?
Athina Gomes MaiaLuiz Felipe Nunes PalharesIrina Gomes MaiaPaulo Daniel Medeiros BraulinoLeila Maria Moreira Beltrão PereiraPublished in: Arquivos de gastroenterologia (2024)
It remains doubtful whether the use of NSBB is deleterious in cirrhotic patients with refractory ascites, however our literature review allows us to conclude that these drugs should not be proscribed in these patients. On the contrary, a doctor-patient decision based on tolerability and hemodynamic parameters certainly seems to be a safe conduct.